Keyphrases
CD8+ T Cells
100%
Primary Tumor
100%
HLA-A2
100%
CD4+
100%
Derived Peptide
100%
MHC Class II
100%
Codon 12
100%
RAS Oncogene
100%
CD8+
75%
Antigen-specific
75%
Oncogene
50%
Point mutation
50%
Vaccination
50%
Lymphocytes
50%
Cytotoxic T Lymphocytes
50%
K-ras
50%
Revaccination
50%
Immunogen
25%
Amino Acid Substitution
25%
T Cell Response
25%
Non-small Cell Lung Cancer (NSCLC)
25%
T Cell Lines
25%
Cancer Patients
25%
Active Immunization
25%
Specific mutation
25%
Phase I Clinical Trial
25%
Peptide Epitopes
25%
Cellular Immune Response
25%
CD4+ T
25%
Single Patient
25%
Cellular Immunity
25%
Functional Capacity
25%
Cysteine
25%
Glycine
25%
Cross-reactivity
25%
T Cell Receptor
25%
Colon Adenocarcinoma
25%
Aspartic Acid
25%
Immunogenic
25%
Cytotoxic T Lymphocyte Epitope
25%
Valine
25%
Metastatic Carcinoma
25%
Passive Immunity
25%
Specific Point
25%
Receptor Recognition
25%
CD4+ T Cell Response
25%
Detox
25%
Class I HLA
25%
Duodenal Carcinoma
25%
KRAS Oncogene
25%
KRAS Protein
25%
Immunology and Microbiology
Cytotoxic T-Cell
100%
T-Helper Cell
100%
Cell Line
100%
Major Histocompatibility Complex
100%
Codon
100%
Oncogene Ras
100%
CD4
75%
Antigen Specificity
75%
CD8
75%
Cytotoxic T Cell
75%
T Cell
50%
Adoptive Immunity
50%
Vaccination Policy
50%
Epitope
50%
Lymphocyte
50%
Point Mutation
50%
Proto Oncogene
50%
Antigen
25%
Amino Acid Substitution
25%
T Cell Receptor
25%
Colon
25%
Precursor
25%
Cross-Reactivity
25%
Immunotherapy
25%
Functional Status
25%
Murine
25%
Oncogene K Ras
25%
Phosphoryl Lipid A
25%